choline has been researched along with MELAS Syndrome in 6 studies
MELAS Syndrome: A mitochondrial disorder characterized by focal or generalized seizures, episodes of transient or persistent neurologic dysfunction resembling strokes, and ragged-red fibers on muscle biopsy. Affected individuals tend to be normal at birth through early childhood, then experience growth failure, episodic vomiting, and recurrent cerebral insults resulting in visual loss and hemiparesis. The cortical lesions tend to occur in the parietal and occipital lobes and are not associated with vascular occlusion. VASCULAR HEADACHE is frequently associated and the disorder tends to be familial. (From Joynt, Clinical Neurology, 1992, Ch56, p117)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the utility of Magnetic Resonance Spectroscopy (MRS) as a biomarker of response to L-arginine in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)." | 3.91 | MELAS: Monitoring treatment with magnetic resonance spectroscopy. ( Chong, RA; DeGiorgio, CM; Galati, A; Hovsepian, DA; Mazumder, R; Mishra, S; Yim, C, 2019) |
| " Mutation carriers included 45 patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS); 11 participants who would develop the MELAS syndrome during follow-up (converters); and 79 participants who would not develop the MELAS syndrome during follow-up (nonconverters)." | 3.80 | Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. ( De Vivo, D; DiMauro, S; Engelstad, KM; Hinton, V; Kaufmann, P; Mao, X; Shungu, D; Weiduschat, N, 2014) |
| "Localized brain proton MR spectra were acquired from patients with different mitochondrial encephalomyopathies (myoclonus epilepsy with ragged-red fibers [MERRF], Kearns-Sayre syndrome [KSS], and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS])." | 3.68 | Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. ( Andermann, F; Arnold, DL; Karpati, G; Mathews, PM; Silver, K, 1993) |
| "Six patients with MELAS (age 28 ± 13 years, 3 [50%] female) and 17 with MSS (age 45 ± 11 years, 7 [41%] female) and 39 sex- and age-matched healthy controls (HC) were enrolled." | 1.62 | Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations. ( Amore, G; Bianchini, C; Caporali, L; Carelli, V; Cortesi, I; Di Vito, L; Evangelisti, S; Gramegna, LL; La Morgia, C; Liguori, R; Lodi, R; Manners, DN; Maresca, A; Talozzi, L; Testa, C; Tonon, C; Valentino, ML, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gramegna, LL | 1 |
| Evangelisti, S | 1 |
| Di Vito, L | 1 |
| La Morgia, C | 1 |
| Maresca, A | 1 |
| Caporali, L | 1 |
| Amore, G | 1 |
| Talozzi, L | 1 |
| Bianchini, C | 1 |
| Testa, C | 1 |
| Manners, DN | 1 |
| Cortesi, I | 1 |
| Valentino, ML | 1 |
| Liguori, R | 1 |
| Carelli, V | 1 |
| Tonon, C | 1 |
| Lodi, R | 1 |
| Wang, R | 1 |
| Hu, B | 1 |
| Sun, C | 1 |
| Geng, D | 1 |
| Lin, J | 1 |
| Li, Y | 1 |
| Hovsepian, DA | 1 |
| Galati, A | 1 |
| Chong, RA | 1 |
| Mazumder, R | 1 |
| DeGiorgio, CM | 1 |
| Mishra, S | 1 |
| Yim, C | 1 |
| Weiduschat, N | 1 |
| Kaufmann, P | 1 |
| Mao, X | 1 |
| Engelstad, KM | 1 |
| Hinton, V | 1 |
| DiMauro, S | 1 |
| De Vivo, D | 1 |
| Shungu, D | 1 |
| Liu, Z | 1 |
| Zheng, D | 1 |
| Wang, X | 1 |
| Zhang, J | 1 |
| Xie, S | 1 |
| Xiao, J | 1 |
| Jiang, X | 1 |
| Mathews, PM | 1 |
| Andermann, F | 1 |
| Silver, K | 1 |
| Karpati, G | 1 |
| Arnold, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations[NCT01532791] | 300 participants (Anticipated) | Observational | 2004-07-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for choline and MELAS Syndrome
| Article | Year |
|---|---|
Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Biomarkers; Cerebellum; Cerebral Cortex; Choline; DNA, Mitoc | 2021 |
Metabolic abnormality in acute stroke-like lesion and its relationship with focal cerebral blood flow in patients with MELAS: Evidence from proton MR spectroscopy and arterial spin labeling.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Glutamic A | 2021 |
MELAS: Monitoring treatment with magnetic resonance spectroscopy.
Topics: Arginine; Aspartic Acid; Brain; Choline; Female; Humans; Magnetic Resonance Spectroscopy; MELAS Synd | 2019 |
Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers.
Topics: Acidosis, Lactic; Adult; Aged; Aspartic Acid; Cerebral Cortex; Choline; Creatine; DNA, Mitochondrial | 2014 |
Apparent diffusion coefficients of metabolites in patients with MELAS using diffusion-weighted MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Child; Choline; Creatinine; Diffusion; Female; Humans; Magn | 2011 |
Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies.
Topics: Aspartic Acid; Brain; Choline; Creatine; Humans; Kearns-Sayre Syndrome; Lactates; Lactic Acid; Magne | 1993 |